740P Response assessment in advanced renal cell carcinoma (mRCC) patients (pts) treated by Nivolumab (N) + Ipilimumab (I): CT volumetric measurement versus RECIST 1.1 response criteria
2020
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI